Health-Related QoL Maintenance in Type of Chronic-Phase Leukemia

Submitted by admin5 on Fri, 11/03/2017 - 13:31

Researchers analyzed the impact of a novel therapy on health-related quality of life (QoL) in patients with a chronic-phase leukemia subtype, according to a recent study published in Cancer (online October 26, 2017; doi:10.1002/cncr.31082).

Since long-term treatment is required for chronic-phase myeloid leukemia (CML), maintaining good QoL is important for patients with the disease.

Hagop M. Kantarjian, MD, University of Texas MD Anderson Cancer Center, and colleagues evaluated patients with Philadelphia chromosome-positive CML and resistance or intolerance to 1 (chronic-phase second-line [CP2L]; n = 284) or more (chronic-phase third-line [CP3L]; n = 119) tyrosine kinase inhibitors. Additionally, all patients included in the study had 264 weeks or more of follow-up.

The EuroQol 5-Dimensions Questionnaire (EQ-5D) and the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu) were administered to patients to assess patient-reported health-related QoL.

Upon completion of treatment, more than half of patients in the CP2L and CP3L cohorts had completed the EQ-5D and FACT-Leu assessments. Results indicated that QoL had been maintained with long-term use of bosutinib. According to the researchers, the EQ-5D and EQ-5D visual analog scale scores had been stable in both cohorts over the course of treatment. The mean FACT-Leu scores had been generally stable over time. However, they were lower in magnitude among CP3L patients compared with CP2L patients.

The researchers noted that FACT-Leu scale scores of a subset of patients with chronic diarrhea (101 in CP2L, 30 in CP3L) had been similar to those of larger cohorts.


Related Content

Dose Escalation of CML Treatment Improves Molecular Response Rates

NCCN Updates Treatment Guidelines for CML


Additionally, for the FACT-Leu scale scores, the researchers observed minimally important differences from baseline for emotional well-being, Functional Assessment of Cancer Therapy–General (FACT-G) Total, FACT-Leu Total, and Functional Assessment of Cancer Therapy Trial Outcome Index (FACT-TOI) in CP2L patients, as well as FACT-Leu Total in CP3L patients.

Minimally important differences were also observed in patients with chronic diarrhea for emotional well-being, FACT-G Total, FACT-Leu Total, and FACT-TOI in those with CP2L CML, and for emotional well-being, FACT-G Total, and FACT-Leu Total in those with CP3L CML.

“Health-related QoL was maintained with long-term bosutinib treatment for patients with CP2L and CP3L CML,” the researchers concluded. —Christina Vogt